Valsartan for Prevention of Recurrent Atrial Fibrillation
Atrial fibrillation is the most common cardiac arrhythmia, and no current therapy is ideal for control of this condition. Experimental studies suggest that angiotensin II–receptor blockers (ARBs) can influence atrial remodeling, and some clinical studies suggest that they may prevent atrial fibrillation. Treatment with valsartan was not associated with a reduction in the incidence of recurrent atrial fibrillation. [more...]
|
|
|
